Francisco J. Esteva - Concepedia

Author

Francisco J. Esteva

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Chiu, Wing-Keung, Esteva, Francisco J., F Esteva, F J Esteva, F. Esteva, F. Esteva A.E, Feng, F. J. Esteva, F.J Esteva, F.J. Esteva, FJ Esteva

455

Publications

27.7K

Citations

H-Index

127

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center NYU Langone Health Breast Cancer Care New York University Memorial Sloan Kettering Cancer Center

About

Francisco J. Esteva is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	70	7.9K
2	Health Sciences	12	13	2K
3	Engineering	2	2	44
4	Natural Sciences	1	1	146
5	Nursing	1	1	30

Francisco J. Esteva

165

Publications

21.1K

Citations

H-Index

Page 1

	Year	Citations
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou, Cancer Cell Trastuzumab ResistancePten Activation ContributesMedicinePharmacologyImmunology	2004	1.8K
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Catharine M. Sturgeon, Michael J. Duffy, Ulf‐Håkan Stenman, Clinical Chemistry	2008	1.1K
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 Dennis J. Slamon, Patrick Neven, Stephen Chia, Journal of Clinical Oncology Advanced Breast CancerFulvestrant V PlaceboBreast OncologyHealth SciencesMedicine	2018	1.1K
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Dennis J. Slamon, Patrick Neven, Stephen Chia, New England Journal of Medicine	2019	797
Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells Rita Nahta, Linda X.H. Yuan, Bing Zhang, Cancer Research	2005	792
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells Rita Nahta, Mien‐Chie Hung, Francisco J. Esteva Cancer Research	2004	599
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer Francisco J. Esteva, Vicente Valero, Daniel J. Booser, Journal of Clinical Oncology	2002	570
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification Andrew D. Seidman, Monica Fornier, Francisco J. Esteva, Journal of Clinical Oncology	2001	548
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways Siyuan Zhang, Wen-Chien Huang, Ping Li, Nature Medicine Trastuzumab ResistanceDrug Resistance AnalysisSignal TransductionCommon Node DownstreamHealth Sciences	2011	513
Planning cancer control in Latin America and the Caribbean Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević, The Lancet Oncology Preventive MedicineMedicineGlobal HealthEpidemiology Of CancerCancer Prevention	2013	496

Page 1